News Feed
Up to $9.5 Million in Debt Financing and $12 Million in Equity Financing.
Company to Advance its Immuno-Dermatology and Inflammatory Bowel Disease Product Candidates
Lead Compound Bertilimumab, First-in-Class Autoimmune Therapy, a Priority
[…]
NASDAQ:EDUC […]
Will Also Participate in Additional Wattenberg Well […]
Wall Street Analyzer’s CEO Interview Series […]
Management Interview […]
Chanticleer Holdings, Inc (NASDAQ:HOTR) President and CEO: Michael Pruitt THIS INTERVIEW HAS EXPIRED
Interview with CEO Mark Smith […]
Interview with CEO Rob Hutchison […]
Copyright © 2019 The Wall Street Analyst, LLC. All rights reserved. Website by MyWebsiteSpot.com